Alexion Pharmaceuticals
Headquartered in Cheshire, Connecticut (USA), Alexion is global biopharmaceutical company focused on the development and delivery of life-transforming therapies for patients with severe and life-threatening rare disorders.
Financial Data
-
31st Dec 18 Source: CRO
- €2.3 billion turnover
-
€1.3 billion
profit - 500 employees
-
31st Dec 17 Source: Estimated
- €321.6 million turnover
- 300 employees
- 4 more years available »
Ranking
By Turnover
(€2.3 billion)- 49th in Top Companies
- 9th in Health
- 7th in Pharma
By Employees
(500)- 367th in Top Companies
- 55th in Health
- 35th in Pharma
- 500
- €2.3 billion
Employees
- Shane Doyle Senior vice president
Latest News
- 5:30am Eason faces a defining chapter in its long history
- Sep 18 European shares fall on Covid-19 case resurgence
- Sep 18 Eason to hold meeting next month to approve €20m payout to shareholders
- Sep 18 Employers in mechanical construction sector to pay 2.7% pay rise after strike threat
- Sep 18 EU signals late call on Apple tax appeal as deadline looms